-+ 0.00%
-+ 0.00%
-+ 0.00%

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Benzinga·10/08/2025 16:46:37
Listen to the news
Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $7 price target.